{"transactions":[{"id":1431352,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Non-Qualified Stock Options","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"15,000 stock options granted upon the effectiveness of the registration statement for the issuer's initial public offering on August 12, 2024, which vest in full on the first anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":8,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431351,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Warrant (Right to Buy)","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":true,"shares":28464,"ownership":{"direct":false,"nature":"By KVP II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":28464},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431350,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":49984,"ownership":{"direct":false,"nature":"By Kairos SPV Fund, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":49984},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431349,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":24138,"ownership":{"direct":false,"nature":"By Kairos-Actuate SPV, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24138},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431348,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":132908,"ownership":{"direct":false,"nature":"By Kairos SPV Fund, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":132908},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431347,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":230597,"ownership":{"direct":false,"nature":"By Kairos-Actuate SPV, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":230597},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431346,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":138889,"ownership":{"direct":false,"nature":"By Kairos SPV Fund, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":138889},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431345,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":146870,"ownership":{"direct":false,"nature":"By KVOI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":146870},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431344,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":69445,"ownership":{"direct":false,"nature":"By KVP II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":69445},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431343,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series B-2 Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":726163,"ownership":{"direct":false,"nature":"By KVOI, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":726163},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431342,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Series B-1 Redeemable Convertible Preferred Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":1058318,"ownership":{"direct":false,"nature":"By KVP II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1058318},"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431341,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":18750,"price":8,"value":150000.0,"ownership":{"direct":false,"nature":"By KVP II, L.P."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":1184795,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431340,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":true,"shares":28464,"price":5.27,"value":150005.28,"ownership":{"direct":false,"nature":"By KVP II, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":1203545,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431339,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":49984,"ownership":{"direct":false,"nature":"By Kairos SPV Fund, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":321781,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431338,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":24138,"ownership":{"direct":false,"nature":"By Kairos-Actuate SPV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":254735,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431337,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":132908,"ownership":{"direct":false,"nature":"By Kairos SPV Fund, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":271797,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431336,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":230597,"ownership":{"direct":false,"nature":"By Kairos-Actuate SPV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":230597,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431335,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":138889,"ownership":{"direct":false,"nature":"By Kairos SPV Fund, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":138889,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431334,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":146870,"ownership":{"direct":false,"nature":"By KVOI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":873033,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431333,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":69445,"ownership":{"direct":false,"nature":"By KVP II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":1175081,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431332,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":726163,"ownership":{"direct":false,"nature":"By KVOI, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":726163,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}},{"id":1431331,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":17359,"kind":"person","name":"THOMSON TODD S","position":1,"cik":"0001225707","reported_name":"THOMSON TODD S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"16.4% Owner"}},{"id":88250,"kind":"person","name":"Kairos SPV Fund LLC","position":2,"cik":"0001788046","reported_name":"Kairos SPV Fund LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"2% Owner"}},{"id":88251,"kind":"person","name":"Kairos Venture Opportunities I, L.P.","position":3,"cik":"0001772438","reported_name":"Kairos Venture Opportunities I, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"5.3% Owner"}},{"id":69840,"kind":"person","name":"Kairos Venture Partners II, L.P.","position":4,"cik":"0001696711","reported_name":"Kairos Venture Partners II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"7.6% Owner"}},{"id":88252,"kind":"person","name":"Kairos-Actuate SPV, L.P.","position":5,"cik":"0001835962","reported_name":"Kairos-Actuate SPV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"1.5% Owner"}}],"security":"Common Stock","published_at":"2024-08-17T01:12:15.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":1058318,"ownership":{"direct":false,"nature":"By KVP II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities of Actuate Therapeutics, Inc. (\"Actuate\") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the \"Kairos Funds\"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC (\"KVI\"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase."}],"balance_after":1105636,"source":{"system":"sec-edgar","filing":"0001104659-24-090619","document":"tm2421960-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652935/000110465924090619/tm2421960-1_4seq1.xml","form_type":"4"}}]}